OTC Stock News

[budfoxfun]

$ENTB .038on high alert this week! Product Pipeline: Bone Marrow and Aplastic Anemia Therapy - A personalized cellular therapeutic product designed to stimulate blood production in patients whose bone marrow is not properly functioning.
Fat stem cell based product to treat bone marrow that has been damaged
Bone marrow damage occurs from radiation, chemo, or chronic conditions
Uses animal’s own fat as source of endothelial cells to heal damaged bone marrow
Tox studies have been successfully completed by Regen BioPharma Inc. the licensor of this technology to Zander Therapeutics.
Aims to provide “natural” replacement to synthetic cytokines
United States Food and Drug Administration Investigational New Drug Application (IND #15376, status cleared for use in humans by Regen BioPharma Inc. -- licensor to Zander Therapeutics Inc.)

http://zandertherapeutics.weebly.com/product-pipeline.html